Report cover image

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Publisher Reach Market Research
Published Jul 29, 2022
Length 28 Pages
SKU # RMR19136488

Description

MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The MarketVue®: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: CIDP report is supported by 8 qualitative interviews with key opinion leaders, a quantitative survey with 26 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Sanofi
• Argenx
• Janssen Pharmaceuticals
• UCB
• Takeda Pharmaceuticals

Key drugs mentioned:
• IVIg (HyQvia)
• Rituximab
• SAR445088
• Efgartigimod (Vyvgart)
• Nipocalimab
• Rozanolixizumab (Rystiggo)

Please note: the online download version of this report is for a global site license.

Table of Contents

28 Pages
1. DISEASE OVERVIEW
A rare, autoimmune neurological disorder characterized by loss of sensation and motor weakness
Figure 1.1. Clinical presentation of CIDP
CIDP is characterized by motor and/or sensory deficits
Table 1.1. CIDP – Typical and atypical variants
Figure 1.2. Neurologist-reported segmentation of their CIDP patient population
Figure 1.3. Neurologist-reported percentage of patients previously misdiagnosed, incorrectly diagnosed, or not diagnosed in a timely manner
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1 – Diagnosed prevalent cases of CIDP by region
Table 2.1 – Diagnosed prevalent and drug-treated patients in the U.S. and EU5
3. DIAGNOSIS AND CURRENT TREATMENT
Diagnosis overview
Figure 3.1. Diagnostic criteria for CIDP based on EFNS/PNS guidelines
Physician insights on diagnosis of CIDP
Majority of CIDP patients require drug treatment
Treatment overview
Figure 3.2. Treatment goals for CIDP
Figure 3.3. Neurologist-reported percentage of patients receiving some form of drug therapy
Treatment flow for CIDP
Figure 3.4. Treatment algorithm for CIDP
Immunoglobulin therapy is the standard of care
Figure 3.5. Current Treatment Patient Share
Figure 3.6. Neurologist (n=26) rating of current effective therapy effectiveness in CIDP
Upsides and downsides of current CIDP treatments
Neurologists’ perspectives on current treatments
IVIg is an effective and safe front-line treatment
Figure 3.7. IVIg’s advantages observed in clinical practice
IVIg therapy is not without challenges
Figure 3.8. Approximately 30% of IVIg-treated patients have a poor/inadequate response/are refractory to IVIg therapy
Key treatment dynamics that shape disease management and drug use in CIDP
Figure 3.9. Must-know CIDP treatment dynamics for now and the future
Immunomodulating therapies are the future of CIDP therapy
Figure 3.10. Important dynamics of CIDP market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in CIDP
Figure 4.2. Physician-reported unmet needs in CIDP
Barriers to care – Physician perspectives
Figure 4.3. Percent of patients who see these factors as barriers to receiving drug therapy
Physician perspectives on unmet needs in CIDP
Figure 4.4. U.S. neurologists’ ranking of the need for new treatments in CIDP
5. PIPELINE ANALYSIS
Overview
Figure 5.1. Number of emerging therapies with clinical trial endpoints that align with unmet needs in CIDP
Table 5.1. Comparison of emerging therapy MoAs
The pipeline for CIDP is active with multiple treatments in late-stage trials
Table 5.2. Comparison of ongoing trials of therapies for CIDP
Although emerging therapies with novel mechanisms are exciting, they may not replace IVIg
Figure 5.2. Percentage of neurologists who rated the following emerging target or approach as “promising”1
6. VALUE & ACCESS
Overview
Table 6.1 – Current therapy pricing
Table 6.2. Typical commercial payer coverage of IV Immune Globulin and Subcutaneous Immune Globulin (e.g., United Healthcare, Aetna, BlueCross BlueShield, Cigna)
Key market access dynamics that will continue to shape treatment use
Figure 6.2. Physician-reported key barriers to drug therapy for CIDP patients
Figure 6.2. Physician-reported key barriers to drug therapy for CIDP patients
7. METHODOLOGY
Primary market research approach
Epidemiology methodology

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us